Associate at Claris Ventures
Check size: Claris Ventures does not publish a standard check-size range on its current official site.
Giuditta Magnifico invests or supports investment decisions through Claris Ventures's published strategy: Build and invest in biopharma companies arising from the Italian research ecosystem around transformational therapies for major unmet patient needs.
Show the unmet need, mechanism and evidence, IP position, development plan, founding scientific team and milestones to the next value inflection.
Exceptional science, strong translational potential, credible intellectual property and teams capable of developing transformational medicines.
Projects outside therapeutics and biopharma, or without strong scientific evidence and Italian ecosystem relevance, are less aligned.